Ignite Creation Date:
2024-05-05 @ 4:50 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00325130
Status:
COMPLETED
Last Update Posted:
2015-03-12
First Post:
2006-05-11
Brief Title:
Concomitant Use of Gardasil V501 Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine With Combined Diphtheria Tetanus Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents V501-025
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
An Open-Label Randomized Multicenter Study of the Safety Tolerability and Immunogenicity of V501 Given Concomitantly With Menactra and ADACEL in Healthy Adolescents 11-17 Years of Age
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Data from this study are expected to demonstrate that V501 Human Papillomavirus HPV Types 6 11 16 18 Recombinant Vaccine when administered concomitantly with a combined diphtheria tetanus pertussis Tdap vaccine and a meningococcal conjugate vaccine in adolescents remains immunogenic and well-tolerated and it does not impair the immunogenicity of the concomitant vaccines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005_092 | None | None | None |